Eli Lilly and Company recently presented phase-three study data on its psoriasis drug ixekizumab during the American Academy of Dermatology's annual meeting.
Ixekizumab is being investigated as a treatment for moderate to severe plaque psoriasis and active psoriatic arthritis.
Approximately 125 million individuals around the world suffer from psoriasis, an immune disease that causes skin cells to grow rapidly. Plaque psoriasis is the most common form and appears as raised, red patches of skin covered by silver scales. Psoriasis can happen anywhere on the body and can increase the risk of many other health conditions, including heart disease, diabetes and depression.
"Moderate to severe plaque psoriasis can significantly impact all aspects of a person's life, including both physical and emotional burdens," Eli Lilly and Company Vice President and Global Brand Development Leader Aarti Shah said. "We are pleased to bring a comprehensive review of data for ixekizumab to this year's American Academy of Dermatology annual meeting, which we believe highlights the potential for ixekizumab -- if approved -- to address the challenges faced by people living with this disease and physicians looking to provide a new treatment option for their patients."
Eli Lilly and Company showcased data regarding ixekizumab throughout 29 abstracts, including both oral and poster presentations. Among the data presented were the efficacy and safety of the treatment for 60 weeks in moderate to severe plaque psoriasis, as well as patient-reported outcomes from the treatment.
